Policymakers are increasingly concerned that a major geopolitical conflict with China could disrupt U.S. drug supply chains, causing widespread drug shortages. While onshoring downstream pharmaceutical production can reduce some risks, de-risking requires a comprehensive strategy at all manufacturing stages, including upstream chemical manufacturing. Given limited funding, policymakers must focus government support where domestic production is strategic, allied partnerships are practical, and trade-offs are unavoidable. To ensure government investments are sustainable, reforms to generic drug reimbursement mechanisms will also be necessary.
What policymakers need to know about China’s role in the US drug supply chains and what to do about it (Marta E. Wosińska – Brookings)
Related articles
